il 15 inhibitors
Start with the article narrative. Use the right sidebar to jump from prose into concept context, nearby graph relationships, and source provenance.
Drugs that silence the innate immune alarm — most relevant for refractory celiac disease where the standard gluten-free diet is no longer enough.
IL-15 inhibitors are a class of biologic drugs that block the activity of interleukin-15 (IL-15), the cytokine that activates the innate immune arm of celiac disease and drives intraepithelial lymphocyte (IEL) proliferation. They represent the most targeted therapeutic approach for refractory celiac disease (RCD) — particularly RCD type 2, where IL-15 drives the aberrant IEL transformation that risks progression to EATL.
Why IL-15 Is the Target
Unlike glutenases or larazotide-acetate (which try to reduce how much gluten reaches the immune system), IL-15 inhibitors work downstream — blocking the immune response itself. IL-15 is particularly important because:
- It activates IELs independently of the HLA-DQ2/DQ8 + T cell pathway
- It drives the aberrant IEL phenotype in RCD type 2
- It maintains the chronic inflammatory state in the gut epithelium even on a GFD
Key Candidates
AMG 714 (Amgen / PRV-015)
- Anti-IL-15 monoclonal antibody
- Phase 2 trials in:
- RCD type 2 — primary target population
- Non-responsive celiac disease — broader NRCD population
- Results suggested biologic activity, but the 2024 therapy-landscape review emphasizes that clinical success has been limited so far
- A broader 2026 review reinforces that this branch remains scientifically compelling but clinically frustrating: symptomatic signals have not translated cleanly into strong mucosal or IEL improvements
- Development status post-Phase 2 remains uncertain
- Newer IL-15-directed programs continue to explore whether this pathway can be blocked more effectively than with earlier antibodies
- The 2024 Drug Discovery Today review highlights CALY-002, TEV-53408, and dual IL-15/IL-21-oriented approaches as signs that the innate/refractory branch is still very much alive
- These remain research-stage rather than standard care
How They Compare to Other Treatments
| Approach | Stage | Best For |
|---|---|---|
| GFD | Standard of care | All celiac patients |
| glutenases | Phase 2/3 | Inadvertent exposure protection |
| Larazotide | Phase 3 (failed) | Intestinal permeability |
| AMG 714 / IL-15 inhibitors | Phase 2 | RCD type 2, NRCD |
| tolerance-induction | Phase 2 | Disease modification |
| JAK inhibitors | Early studies | RCD |
A 2023 RCD-focused review adds an important caution: IL-15 pathway targeting remains intellectually attractive, but the practical RCD literature still leans much more heavily on budesonide-first care and selected escalation strategies than on successful cytokine-directed rescue.
Potential Risks
IL-15 plays a role in normal immune surveillance (including tumour surveillance). Long-term IL-15 blockade theoretically carries infection and malignancy risks — important given that RCD type 2 already has elevated EATL risk.
Source Basis
Current synthesis also incorporates:
raw/PIIS0016508524004165.pdf(How Future Pharmacologic Therapies for Celiac Disease Will Complement the Gluten-Free Diet, 2024), which is particularly useful for placing IL-15 blockade in the RCD/innate-immunity branch rather than the accidental-exposure branchraw/1-s2.0-S1359644624002381-main.pdf(New developments in celiac disease treatments, 2024), which is especially useful for mapping the newer IL-15 program names and placing them inside the broader drug-development pipelineraw/biomedicines-14-00029-v2.pdf(Rethinking Celiac Disease Management: Treatment Approaches Beyond the Gluten-Free Diet, 2026), which is especially useful for underscoring the mismatch between biologic rationale and still-limited clinical success
Related Concepts
il-15 | refractory-celiac | intraepithelial-lymphocytes | eatl | cytokines-celiac | glutenases | larazotide-acetate | tolerance-induction